MetLife (MET)
(Delayed Data from NYSE)
$74.34 USD
+0.49 (0.66%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $74.34 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$74.34 USD
+0.49 (0.66%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $74.34 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth B Momentum B VGM
Zacks News
Progressive's April Earnings Grow on Robust Revenue Rise
by Zacks Equity Research
Rise in revenues offsets increase in expenses, driving Progressive's (PGR) bottom line in April.
Kemper (KMPR) Hits 52-Week High: Will the Stock Rally Ahead?
by Zacks Equity Research
Kemper's (KMPR) robust Q1 performance along with its strategic initiatives to ramp up growth drives the stock to reach a 52-week high in the last trading session.
Add Value to Your Investment With These 4 Low P/CF Stocks
by Zacks Equity Research
When it comes to the investment market, experts consider value style as one of the most effective approaches.
CNO Financial Rewards Investors With 11% Dividend Increase
by Zacks Equity Research
CNO Financial's (CNO) 11% dividend hike reflects its strong operational growth.
Top Research Reports for Schwab, NextEra & MetLife
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Schwab (SCHW), NextEra (NEE) and MetLife (MET).
MetLife (MET) Q1 Earnings Top Estimates, Revenues Rise Y/Y
by Zacks Equity Research
MetLife's (MET) Q1 rides high on improved performances across the U.S., Asia, EMEA and MetLife Holdings Segments plus a favorable impact of the reformed U.S. tax law.
Insurers' Q1 Earnings Due on May 2: AIG, LNC, MET, PRU, XL
by Zacks Equity Research
Insurance stocks in the first quarter are likely to benefit from a positive operating environment, fundamental strength of insurers and a lower tax rate.
MetLife (MET) Q1 Earnings to Buoy on Revenue Growth
by Zacks Equity Research
MetLife (MET) Q1 earnings should see upside from higher revenues in property and casualty business, a low tax rate, high investment income.
The Zacks Analyst Blog Highlights: Facebook, UnitedHealth, Pfizer, McDonald's and MetLife
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Facebook, UnitedHealth, Pfizer, McDonald's and MetLife
MetLife Bolsters Operations in China With Tencent's WeSure
by Zacks Equity Research
MetLife's (MET) partnerships aim at delivering high quality products to customers at lower cost along with convenience and ease as a bonus.
Top Research Reports for UnitedHealth, Morgan Stanley & Anheuser-Busch
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including UnitedHealth (UNH), Morgan Stanley (MS) and Anheuser-Busch (BUD).
Top Analyst Reports for Bristol-Myers, Honda & Danaher
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Bristol-Myers (BMY), Honda (HMC), and Danaher (DHR).
MetLife (MET) Q4 Earnings Beat, Revenues Miss Estimates
by Zacks Equity Research
Robust EMEA and Latin America segments aid MetLife (MET) in Q4. However, a dull performance at U.S., Asia and MetLife Holdings partially offsets this upside.
Why Earnings Season Could Be Great for MetLife (MET)
by Zacks Equity Research
MetLife (MET) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Top Research Reports for Apple, JPMorgan & AbbVie
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Apple (AAPL), JPMorgan (JPM) and AbbVie (ABBV).
Arthur J. Gallagher's Buyout to Fortify Water Utility Insurance
by Zacks Equity Research
Arthur J. Gallagher (AJG) continues its inorganic growth strategy on the back of AquaSurance acquisition.
Hartford Q4 Earnings Might be Drained by Tax Act & Cat Loss
by Zacks Equity Research
Hartford (HIG) expects the recent tax law and catastrophe losses to impact its fourth-quarter 2017 results adversely. However, the company remains optimistic about the long-term benefits from it.
Is MetLife (MET) a Great Stock for Value Investors?
by Zacks Equity Research
Let's see if MetLife Inc. (MET) stock is a good choice for value-oriented investors right now from multiple angles.
Fed Hikes Rates: Pick 6 Value Stocks from Insurance Industry
by Zacks Equity Research
Amid an improving macro backdrop, we select six value stocks with strong fundamentals from the insurance industry for better returns.
Fed Hikes Rate: 4 Stocks to Add Value to Your Portfolio
by Zacks Equity Research
The Fed, who have chalked out a detailed plan to shrink $4.5 trillion portfolio of Treasury bonds and mortgage-backed securities, continue to advocate three more hikes next year.
CNO Financial Grows on Solid Cash Position, High Debt Hurts
by Zacks Equity Research
Although CNO Financial's (CNO) solid financial health continues to impress, rising level of debt weighs on the bottom line.
Aon's Inorganic Growth Impresses, Rising Debt Level a Drag
by Zacks Equity Research
Although Aon plc's (AON) top line grows on organic strategies, continuously rising level of debt weighs on its bottom line.
What Should You Expect From The FOMC Meet?
by Zacks Equity Research
What Should You Expect From The FOMC Meet?
Awaiting the Inevitable Interest Rate Hike
by Mark Vickery
The Fed's slow and steady methodology has taken longer than many had anticipated to reach equilibrium, but we are definitely there now.
MGIC Investment (MTG) Reports Robust November Business Data
by Zacks Equity Research
Driven by declining claim payments and improvement in new business written, MGIC Investment (MTG) posts solid figures for November and is likely to retain the momentum in the future.